Minutes: confirmed

Date and Time: Tuesday 9 April 2019, 10am – 1pm

Present:

1. Dr Jane Adam Present for all notes
2. Dr Brian Shine Present for all notes
3. Dr Alice Turner Present for all notes
4. Dr Graham Ash Present for all notes
5. Professor John McMurray Present for all notes
6. Dr John Watkins Present for all notes
7. Dr Justin Daniels Present for all notes
8. Dr Mark Upton Present for all notes
9. Mr Min Ven Teo Present for all notes
10. Dr Mohit Sharma Present for all notes
11. Professor Olivia Wu Present for all notes
12. Dr Paul Robinson Present for all notes
13. Mr Richard Ballerand Present for all notes
14. Dr Rita Faria Present for all notes
15. Dr Roger Whittaker Present for all notes
16. Mr Stephen Sharp Present for all notes
17. Dr Steve Edwards Present for all notes
18. Dr Sumithra Maheswaran Present for all notes

In attendance:

Helen Knight Programme Director, National Institute for Health and Care Excellence Present for all notes

Janet Robertson Associate Director, National Institute for Health and Care Excellence Present for all notes

Thomas Feist Project Manager, National Institute for Health and Care Excellence Present for all notes

Marcia Miller Administrator, National Institute for Health and Care Excellence Present for all notes

Juliet Kenny Technical Analyst, National Institute for Present for all notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Position and Affiliation</th>
<th>Notes Present For</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rufaro Kausi</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Thomas Strong</td>
<td>NICE CDF, Technical Adviser</td>
<td>Present for notes 6 to 8</td>
</tr>
<tr>
<td>Dr Geoff Frampton</td>
<td>Southampton Health Technology Assessments Centre Evidence Review Group</td>
<td>Present for notes 1 to 5</td>
</tr>
<tr>
<td>Professor Joanne Lord</td>
<td>Southampton Health Technology Assessments Centre Evidence Review Group</td>
<td>Present for notes 1 to 5</td>
</tr>
<tr>
<td>Dr Charlotte Proby</td>
<td>Clinical expert, Professor of Dermatology, University of Dundee, nominated by RCP</td>
<td>Present for notes 1 to 5</td>
</tr>
<tr>
<td>Dr Andrew Sykes</td>
<td>Clinical expert, Consultant Clinical Oncologist, Christie Hospital, nominated by Sanofi</td>
<td>Present for notes 1 to 5</td>
</tr>
<tr>
<td>Clair McGarr</td>
<td>Patient expert, Skin Cancer Specialist Nurse, nominated by the British Association of Skin Cancer Specialist Nurses</td>
<td>Present for notes 1 to 5</td>
</tr>
<tr>
<td>Professor Peter Clark</td>
<td>Cancer Drugs Fund Clinical Lead</td>
<td>Present for all notes</td>
</tr>
<tr>
<td><strong>Non-public attendees:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adam Storrow</td>
<td>Business Analyst, NICE</td>
<td>Present for all notes</td>
</tr>
</tbody>
</table>
Notes

Minutes from the meeting

1. The committee approved the minutes of the committee meeting held on Tuesday 12 March 2019.

2. Apologies were received from: Dr Jeremy Braybrooke, Dr Minal Bakhai, Mr Adrian Griffin, Ms Ellen Rule, Ms Pamela Rees and Mrs Sarah Parry.

Appraisal of Cemiplimab for treating cutaneous squamous cell carcinoma [ID1367]

Part 1 – Closed session

3. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Sanofi.

4. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.

   4.1. Dr Paul Robinson declared for transparency that he is employed by Merck Sharp and Dohme who make a similar product (PD1). There is no license pending for this indication.

   4.2. Mr Richard Ballerand declared for transparency that he attended the European Medicines Agency as a European Patient Expert in August 2018 and in March this year he attended a Scientific Advice Procedures Panel as a Lay Panelist for Cemiplimab.

   4.2.1. The declarations made were not considered to be a conflict of interest according to the Policy on declaring and managing interest for NICE advisory committees

   4.3. No further conflicts of interest were declared for this appraisal.

5. The Chair introduced the lead team, Dr Roger Whittaker and Dr Rita Faria and who gave presentations on the clinical effectiveness and cost effectiveness of cemiplimab for treating cutaneous squamous cell carcinoma.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

6. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
7. The committee decision was based on consensus.

8. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**
Thursday 16 May 2019, 10am at Prospero House, 241 Borough High Street, SE1 1GA